Patents Represented by Attorney Len Smith

Find this attorney in the Justia Lawyer Directory

  • Adaptive interactive preceptored teaching system
    Patent number: 6974328
    Abstract: An adaptive interactive preceptored teaching system for the remote education of a student provides lessons, obtains the student's profile, uses the profile to select one of the lessons to be sent to the student, and sends that lesson to the student. A method for remote care of a diabetic patient involves providing lessons, obtaining the patient's profile, using the profile to select a lesson to be sent to the patient, sending that lesson to the patient, offering the patient information reflecting the patient's health, and offering the patient's healthcare provider information regarding at least one of the patient's study of the lesson, the patient's health, and the patient's medical appointments. Communication can take place via the Internet, and can be effected in a secure manner.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: December 13, 2005
    Assignees: Noyo Nordisk Pharmaceuticals, Inc., Mayo Clinic
    Inventors: Henrik Aspe, Geoffrey S. Gates
  • Meiosis regulating compounds
    Patent number: 6884796
    Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: April 26, 2005
    Assignees: NovoNordisk A/S, Schering AG
    Inventors: Peter Faarup, Frederick Christian Grønvald, Thorsten Blume, Anthony Murray, Jens Breinholt
  • Insulin and IGF-1 receptor agonists and antagonists
    Patent number: 6875741
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: April 5, 2005
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
  • Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
    Patent number: 6858587
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: February 22, 2005
    Assignee: Novo Nordisk Pharmaceuticals, Inc.
    Inventors: Brit Binow Sorensen, Lars Christian Petersen
  • Glucagon antagonists/inverse agonists
    Patent number: 6821960
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: November 23, 2004
    Assignee: Noyo Nordisk Pharmaceuticals, Inc.
    Inventors: Anker Steen Jørgensen, Peter Madsen